Therapeutic options in recurrent glioblastoma—An update

Addeo, 2011, A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma, J. Neurooncol., 102, 417, 10.1007/s11060-010-0329-z Balmaceda, 2008, Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas, Cancer, 112, 1139, 10.1002/cncr.23167 Barbagallo, 2008, ‘Recurrent’ glioblastoma multiforme, when should we reoperate, Br. J. Neurosurg., 22, 452, 10.1080/02688690802182256 Batchelor, 2010, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J. Clin. Oncol., 28, 2817, 10.1200/JCO.2009.26.3988 Batchelor, 2013, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, J. Clin. Oncol., 31, 3212, 10.1200/JCO.2012.47.2464 Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol., 14, 29, 10.1016/S1470-2045(12)70477-1 Berrocal, 2010, Extended-schedule dose-dense temozolomide in refractory gliomas, J. Neurooncol., 96, 417, 10.1007/s11060-009-9980-7 Bloch, 2012, Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article, J. Neurosurg., 117, 1032, 10.3171/2012.9.JNS12504 Bloch, 2014, Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial, Neuro Oncol., 16, 274, 10.1093/neuonc/not203 Bonekamp, 2015, Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1 – and T2 (*) – based bolus techniques, J. Magn. Reson. Imaging, 42, 87, 10.1002/jmri.24756 Brada, 2001, Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, Ann. Oncol., 12, 259, 10.1023/A:1008382516636 Brada, 2010, Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma, J. Clin. Oncol., 28, 4601, 10.1200/JCO.2009.27.1932 Brandes, 2001, Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study, Ann. Oncol., 12, 255, 10.1023/A:1008336732273 Brandes, 2002, Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study, Oncology, 63, 38, 10.1159/000065718 Brandes, 2004, How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial, Neurology, 63, 1281, 10.1212/01.WNL.0000140495.33615.CA Brandes, 2004, First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia, J. Clin. Oncol., 22, 1598, 10.1200/JCO.2004.11.019 Brandes, 2004, Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO), J. Clin. Oncol., 22, 4779, 10.1200/JCO.2004.06.181 Brandes, 2006, Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO), Br. J. Cancer, 95, 1155, 10.1038/sj.bjc.6603376 Brandes, 2009, Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO), Cancer Chemother. Pharmacol., 64, 769, 10.1007/s00280-009-0926-8 Brandes, 2015, A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma, J. Clin. Oncol., 33, 33, 10.1200/jco.2015.33.15_suppl.2014 Cabrera, 2013, Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial, Int. J. Radiat. Oncol. Biol. Phys., 86, 873, 10.1016/j.ijrobp.2013.04.029 Chamberlain, 2014, A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC), J. Neurooncol., 118, 335, 10.1007/s11060-014-1437-y Chan, 2005, Temozolomide in the treatment of recurrent malignant glioma in Chinese patients, Hong Kong Med. J., 11, 452 Chua, 2004, Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme, Neuro Oncol., 6, 38, 10.1215/S1152851703000188 Combs, 2007, Radiotherapeutic alternatives for previously irradiated recurrent gliomas, BMC Cancer, 7, 167, 10.1186/1471-2407-7-167 Combs, 2013, Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma, Acta Oncol., 52, 147, 10.3109/0284186X.2012.692882 Desjardins, 2012, Bevacizumab and daily temozolomide for recurrent glioblastoma, Cancer, 118, 1302, 10.1002/cncr.26381 Dhermain, 2004, Role of radiotherapy in recurrent gliomas, Bull. Cancer, 91, 883 de Groot, 2011, Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study, J. Clin. Oncol., 29, 2689, 10.1200/JCO.2010.34.1636 Ellingson, 2014, Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma, AJNR Am. J. Neuroradiol., 35, 673, 10.3174/ajnr.A3748 Ellingson, 2015, Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials, Neuro Oncol., 17, 1188 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N. Engl. J. Med., 343, 1350, 10.1056/NEJM200011093431901 Fabrini, 2009, A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma, J Neurooncol, 92, 79, 10.1007/s11060-008-9739-6 Field, 2015, Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma, Neuro Oncol., 17, 1504, 10.1093/neuonc/nov104 Flieger, 2014, Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option, J. Neurooncol., 117, 337, 10.1007/s11060-014-1394-5 Fogh, 2010, Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas, J. Clin. Oncol., 28, 3048, 10.1200/JCO.2009.25.6941 Franceschi, 2015, The effect of re-operation on survival in patients with recurrent glioblastoma, Anticancer Res., 35, 1743 Friday, 2012, Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study, Neuro Oncol., 14, 215, 10.1093/neuonc/nor198 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 27, 4733, 10.1200/JCO.2008.19.8721 Galanis, 2009, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study, J. Clin. Oncol., 27, 2052, 10.1200/JCO.2008.19.0694 Galanis, 2013, Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial, Clin. Cancer Res., 19, 4816, 10.1158/1078-0432.CCR-13-0708 Galanis, 2015, NCCTG N0872 (Alliance): a randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM), J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2004 Galldiks, 2015, Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET, Eur. J. Nucl. Med. Mol. Imaging, 42, 685, 10.1007/s00259-014-2959-4 Gan, 2015, A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM), J. Clin. Oncol., 32, 5s Gaviani, 2011, Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients, J. Neurooncol., 104, 617, 10.1007/s11060-010-0515-z Ghiaseddin, 2015, Phase II study of bevacizumab and vorinostat for recurrent glioblastoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2034 Gilbert, 2009, RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM), J. Clin. Oncol., 27, 10.1200/jco.2009.27.15_suppl.2011 Gilbert, 2012, Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery, J. Neurooncol., 106, 147, 10.1007/s11060-011-0650-1 Gorlia, 2012, New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials, Eur. J. Cancer, 48, 1176, 10.1016/j.ejca.2012.02.004 Grosu, 2005, Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 63, 511, 10.1016/j.ijrobp.2005.01.056 Groves, 2009, Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme, Br. J. Cancer, 101, 615, 10.1038/sj.bjc.6605189 Guyotat, 2000, Is reoperation for recurrence of glioblastoma justified, Oncol. Rep., 7, 899 Han, 2014, Phase II trial of 7days on/7days off temozolmide for recurrent high-grade glioma, Neuro Oncol., 16, 1255, 10.1093/neuonc/nou044 Hasselbalch, 2010, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial, Neuro Oncol., 12, 508 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N. Engl. J. Med., 352, 997, 10.1056/NEJMoa043331 Hovey, 2015, Continuing or ceasing bevacizumab at disease progression: results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2003 Hundsberger, 2013, Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas, J. Neurooncol., 112, 133, 10.1007/s11060-013-1044-3 Hunn, 2015, Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme, J. Neurooncol., 121, 319, 10.1007/s11060-014-1635-7 Iwamoto, 2010, Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02), Neuro Oncol., 12, 855, 10.1093/neuonc/noq025 Johnson, 2012, Glioblastoma survival in the United States before and during the temozolomide era, J. Neurooncol., 107, 359, 10.1007/s11060-011-0749-4 Keime-Guibert, 2007, Radiotherapy for glioblastoma in the elderly, N. Engl. J. Med., 356, 1527, 10.1056/NEJMoa065901 Khan, 2002, A phase II study of extended low-dose temozolomide in recurrent malignant gliomas, Neuro Oncol., 4, 39, 10.1215/15228517-4-1-39 Kickingereder, 2015, Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma, Neuro Oncol., 17, 1139, 10.1093/neuonc/nov028 Kickingereder, 2015, Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab, J. Neurooncol., 121, 373, 10.1007/s11060-014-1644-6 Kong, 2006, A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma, Oncol. Rep., 16, 1117 Kong, 2010, Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma, Neuro Oncol., 12, 289, 10.1093/neuonc/nop030 Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J. Clin. Oncol., 27, 740, 10.1200/JCO.2008.16.3055 Kreisl, 2009, A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM), J. Neurooncol., 92, 99, 10.1007/s11060-008-9741-z Kreisl, 2012, A phase I/II trial of vandetanib for patients with recurrent malignant glioma, Neuro Oncol., 14, 1519, 10.1093/neuonc/nos265 Kreisl, 2013, Continuous daily sunitinib for recurrent glioblastoma, J. Neurooncol., 111, 41, 10.1007/s11060-012-0988-z Lamborn, 2008, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas, Neuro Oncol., 10, 162, 10.1215/15228517-2007-062 Lassen, 2013, Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme, Anticancer Res., 33, 1657 Lassen, 2015, Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma, Neuro Oncol., 17, 1007, 10.1093/neuonc/nov019 Lassen, 2015, A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM), J. Clin. Oncol., 33, 33, 10.1200/jco.2015.33.15_suppl.2044 Lassman, 2015, Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627), Neuro Oncol., 17, 992, 10.1093/neuonc/nov011 Lee, 2015, Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma, Neuro Oncol., 17, 862, 10.1093/neuonc/nou350 Macdonald, 1990, Response criteria for phase II studies of supratentorial malignant glioma, J. Clin. Oncol., 8, 1277, 10.1200/JCO.1990.8.7.1277 Malmstrom, 2012, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial, Lancet Oncol., 13, 916, 10.1016/S1470-2045(12)70265-6 McNamara, 2014, Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression, J. Neurooncol., 117, 147, 10.1007/s11060-014-1366-9 Minniti, 2015, Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas, J. Neurooncol., 122, 559, 10.1007/s11060-015-1745-x Miwa, 2014, Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy, Radiat. Oncol., 9, 181, 10.1186/1748-717X-9-181 Moller, 2012, A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy, Acta Oncol., 51, 797, 10.3109/0284186X.2012.681063 Muhic, 2013, Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme, J. Neurooncol., 111, 205, 10.1007/s11060-012-1009-y Nagane, 2007, Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide, Jpn. J. Clin. Oncol., 37, 897, 10.1093/jjco/hym132 Nagane, 2012, Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma, Jpn. J. Clin. Oncol., 42, 887, 10.1093/jjco/hys121 Nava, 2014, Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997–2010, Neuro Oncol., 16, 719, 10.1093/neuonc/not316 Norden, 2013, Phase 2 study of dose-intense temozolomide in recurrent glioblastoma, Neuro Oncol., 15, 930, 10.1093/neuonc/not040 Pan, 2012, A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma, J. Neurooncol., 110, 111, 10.1007/s11060-012-0943-z Park, 2010, Scale to predict survival after surgery for recurrent glioblastoma multiforme, J. Clin. Oncol., 28, 3838, 10.1200/JCO.2010.30.0582 Park, 2013, A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma, Neuro Oncol., 15, 1096, 10.1093/neuonc/not069 Peereboom, 2013, NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme, Neuro Oncol., 15, 490, 10.1093/neuonc/nos322 Perry, 2010, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J. Clin. Oncol., 28, 2051, 10.1200/JCO.2009.26.5520 Pitz, 2015, Phase II study of PX-866 in recurrent glioblastoma, Neuro Oncol., 17, 1270 Prados, 2004, Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study, Neuro Oncol., 6, 33, 10.1215/S1152851703000309 Puduvalli, 2015, Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102), J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2012 Quinn, 2009, Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma, J. Clin. Oncol., 27, 1262, 10.1200/JCO.2008.18.8417 Radbruch, 2014, Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7Tesla: a feasibility study, PLoS One, 9, e110727, 10.1371/journal.pone.0110727 Raizer, 2010, A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas, Cancer, 116, 5297, 10.1002/cncr.25462 Ratai, 2013, Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677, Neuro Oncol., 15, 936, 10.1093/neuonc/not044 Reardon, 2005, Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma, Cancer, 104, 1478, 10.1002/cncr.21316 Reardon, 2008, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, J. Clin. Oncol., 26, 5610, 10.1200/JCO.2008.16.7510 Reardon, 2009, Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study, Br. J. Cancer, 101, 1986, 10.1038/sj.bjc.6605412 Reardon, 2011, Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy, J. Neurooncol., 103, 371, 10.1007/s11060-010-0403-6 Reardon, 2011, Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma, J. Neurooncol., 101, 57, 10.1007/s11060-010-0217-6 Reardon, 2012, Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma, J. Neurooncol., 107, 155, 10.1007/s11060-011-0722-2 Reardon, 2013, A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma, Clin. Cancer Res., 19, 900, 10.1158/1078-0432.CCR-12-1707 Reardon, 2015, Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma, Neuro Oncol., 17, 430 Reardon, 2015, ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2009 Rieger, 2014, ERGO: a pilot study of ketogenic diet in recurrent glioblastoma, Int. J. Oncol., 44, 1843, 10.3892/ijo.2014.2382 Ryu, 2014, The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline, J. Neurooncol., 118, 489, 10.1007/s11060-013-1337-6 Sampson, 2015, Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.3010 Santoni, 2012, Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: a phase II study, Oncol. Lett., 4, 799, 10.3892/ol.2012.788 Sathornsumetee, 2010, Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma, Neuro Oncol., 12, 1300, 10.1093/neuonc/noq099 Schijns, 2015, First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity, Vaccine, 33, 2690, 10.1016/j.vaccine.2015.03.095 Schmainda, 2014, Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma, Neuro Oncol., 16, 880, 10.1093/neuonc/not216 Scoccianti, 2008, Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience, Anticancer Drugs, 19, 613, 10.1097/CAD.0b013e3283005075 Sepulveda, 2015, A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma, Clin. Transl. Oncol., 17, 743, 10.1007/s12094-015-1304-0 Silvani, 2004, Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients, J. Neurooncol., 66, 203, 10.1023/B:NEON.0000013479.64348.69 Soffietti, 2014, Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology), J. Neurooncol., 116, 533, 10.1007/s11060-013-1317-x Stark-Vance, 2005, Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, Neuro Oncol., 7, 369 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, 987, 10.1056/NEJMoa043330 Stupp, 2011, Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma: a phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group, Ann. Oncol., 22, 2144, 10.1093/annonc/mdq729 Stupp, 2012, NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality, Eur. J. Cancer, 48, 2192, 10.1016/j.ejca.2012.04.011 Suchorska, 2015, Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR trial, Neurosurgery, 62, 209, 10.1227/01.neu.0000467098.06935.3d Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol., 15, 943, 10.1016/S1470-2045(14)70314-6 Verhoeff, 2010, Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma, Ann. Oncol., 21, 1723, 10.1093/annonc/mdp591 Vredenburgh, 2007, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, J. Clin. Oncol., 25, 4722, 10.1200/JCO.2007.12.2440 Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin. Cancer Res., 13, 1253, 10.1158/1078-0432.CCR-06-2309 van den Bent, 2009, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034, J. Clin. Oncol., 27, 1268, 10.1200/JCO.2008.17.5984 Weathers, 2015, A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.2005 Weller, 2013, Standards of care for treatment of recurrent glioblastoma—are we there yet, Neuro Oncol., 15, 4, 10.1093/neuonc/nos273 Weller, 2014, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol., 15, e395, 10.1016/S1470-2045(14)70011-7 Weller, 2015, MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial, Clin. Cancer Res., 21, 2057, 10.1158/1078-0432.CCR-14-2737 Wen, 2010, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J. Clin. Oncol., 28, 1963, 10.1200/JCO.2009.26.3541 Wen, 2010, Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB), J. Clin. Oncol., 28, 10.1200/jco.2010.28.15_suppl.2006 Wen, 2011, A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma, Neuro Oncol., 13, 437, 10.1093/neuonc/noq198 Wen, 2010, American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section, Expert Rev. Anticancer Ther., 10, 1367, 10.1586/era.10.117 Wick, 2004, One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma, Neurology, 62, 2113, 10.1212/01.WNL.0000127617.89363.84 Wick, 2007, Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma, J. Clin. Oncol., 25, 3357, 10.1200/JCO.2007.10.7722 Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J. Clin. Oncol., 28, 1168, 10.1200/JCO.2009.23.2595 Wick, 2012, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, Lancet Oncol., 13, 707, 10.1016/S1470-2045(12)70164-X Wick, 2014, A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma, Clin. Cancer Res., 20, 6304, 10.1158/1078-0432.CCR-14-0951-T Wick, 2015, Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial, Neuro Oncol., 17, 10.1093/neuonc/nov306 Woernle, 2015, Efficacy of surgery and further treatment of progressive glioblastoma, World Neurosurg., 84, 301, 10.1016/j.wneu.2015.03.018 Yong, 2014, Residual tumor volume and patient survival following reoperation for recurrent glioblastoma, J. Neurosurg., 121, 802, 10.3171/2014.6.JNS132038 Yung, 2000, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br. J. Cancer, 83, 588, 10.1054/bjoc.2000.1316